Here are 12 report highlights:
1. J&J noted an increase of 4.2 percent in third quarter sales, compared to the third quarter of 2015.
2. The company’s operational sales rose 4.3 percent in the third quarter.
3. New products, like IMBRUVICA and DARZALEX, as well as core products drove the company’s worldwide operational results.
4. Third quarter domestic sales increased 6.7 percent and international sales rose 1.5 percent.
5. The company’s third quarter net earnings were $4.3 billion and diluted earnings per share were $1.53.
6. Worldwide consumer sales decreased 1.6 percent to $3.3 billion, compared to the third quarter of 2015.
7. Worldwide pharmaceutical sales increased 9.2 percent to $8.4 billion, compared to the third quarter of 2015.
8. J&J’s worldwide medical devices sales hit $6.2 billion in the third quarter of 2016, reflecting a 1.1 percent increase over the same period the year prior.
9. J&J held its sales guidance for the full year of 2016 at $71.5 billion to $72.2 billion.
10. The company updated its adjusted earning guidance for the full year of 2016 to $6.68 to $6.73 per share.
11. The FDA approved the company’s INVOKAMET XR, for treatment of type 2 diabetes, and STELARA, for treatment of Crohn’s disease.
12. In the third quarter, J&J entered a definitive agreement to acquire Abbott Medical Optics for $4.32 billion in cash.
More articles on devices:
3D-printed Align brace offers customizable option for scoliosis patients: 5 highlights
Lourdes Burlington medical center installs 1st Mazor system in South Jersey: 4 highlights
Comparative analysis on medical device quality: New report issued
